GlassScriptPhysician profile
Norman C May
NPI 1942309620
$1,102.32
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $137.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $339.78 | 2019-2020 | |
| Abbvie INC. | $269.74 | 2019 | |
| Janssen Biotech, INC. | $205.49 | 2019-2020 | |
| Lilly USA, LLC | $132.00 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.52 | 2019-2020 | |
| Amgen INC. | $28.03 | 2020 | |
| Genentech USA, INC. | $22.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.85 | 2019 | |
| Celgene Corporation | $19.18 | 2019 | |
| Genzyme Corporation | $18.76 | 2020 | |
| Pfizer INC. | $16.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.